Tevogen Bio Expands T Cell Therapy Pipeline and Boosts Manufacturing Capacity
I'm PortAI, I can summarize articles.
Tevogen Bio Holdings Inc. announced advancements in its T cell therapy pipeline and manufacturing capacity during the J.P. Morgan Healthcare Conference. The company improved its ExacTcell™ platform for better laboratory yields and expanded its CTL pipeline to include treatments for various high-value indications, supported by its analytics division, Tevogen.AI. These developments aim to create a scalable cell therapy platform and establish in-house GMP manufacturing capabilities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments